4-tert.-Butyl-chinuclidin | 45980-26-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 奎宁环
• 英文名称: 4-tert.-Butyl-chinuclidin
• 英文别名: 4-tert-butyl-1-aza-bicyclo[2.2.2]octane；1-Azabicyclo(2.2.2)octane, 4-(1,1-dimethylethyl)-；4-tert-butyl-1-azabicyclo[2.2.2]octane
• CAS: 45980-26-5
• 化学式: C₁₁H₂₁N
• 分子量: 167.294
• InChiKey: XRKRFBOJYJUTLW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
  申请人：Chu Daniel

  公开号：US20090197863A1

  公开（公告）日：2009-08-06

  A compound having the structure set forth in Formula (I) or Formula (II): wherein the variables Y, R 1 , R 2 , R 3 , and R 4 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.

  具有以下式(I)或式(II)所示结构的化合物： 其中变量Y，R1，R2，R3和R4如本文所定义。本文提供了聚(ADP-核糖)聚合酶活性的抑制剂。本文还描述了包括至少一种本文描述的化合物的药物组合物，以及使用本文描述的化合物或药物组合物治疗通过抑制PARP活性改善的疾病、疾病和症状。
• NOVEL INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
  申请人：CHU Daniel

  公开号：US20090062268A1

  公开（公告）日：2009-03-05

  A compound having the structure set forth in Formula (I): wherein the variables Y, R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein. Compounds described herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of such compounds and pharmaceutical compositions to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.

  具有以下式（I）所示结构的化合物： 其中变量Y，R1，R2，R3，R4和R5如本文所定义。本文描述的化合物是聚(ADP-核糖)聚合酶活性的抑制剂。本文还描述了包括至少一种本文描述的化合物的药物组合物，以及利用这些化合物和药物组合物治疗通过抑制PARP活性而改善的疾病、疾病和症状。
• ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME
  申请人：Ensinger Carol L.

  公开号：US20090221821A1

  公开（公告）日：2009-09-03

  The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A 1 receptor. Adenosine A 1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable. In one embodiment, the invention features a compound of formula I:

  该发明基于发现，公式I化合物是意外地高效和选择性地抑制腺苷A1受体的抑制剂。腺苷A1拮抗剂可用于预防和/或治疗许多疾病，包括心脏和循环系统疾病，中枢神经系统退行性疾病，呼吸系统疾病以及许多适合利尿治疗的疾病。在一种实施例中，该发明涉及公式I的化合物：
• Adenosine receptor antagonists and methods of making and using the same
  申请人：Kiesman F. William

  公开号：US20070015732A1

  公开（公告）日：2007-01-18

  The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A 1 receptor. Adenosine A 1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable. In one embodiment, the invention features a compound of formula I:

  该发明基于发现，公式I的化合物意外地具有高度有效和选择性的腺苷A1受体抑制剂。腺苷A1拮抗剂可用于预防和/或治疗许多疾病，包括心脏和循环疾病、中枢神经系统退行性疾病、呼吸系统疾病以及许多适合利尿治疗的疾病。在一种实施例中，该发明涉及公式I的化合物：
• DIPHENYL SUBSTITUTED ALKANES
  申请人：Ogawa Anthony

  公开号：US20100190761A1

  公开（公告）日：2010-07-29

  The instant invention provides compounds of Formula I which are 5-lipoxygenase activating protein inhibitors: formula (I). Compounds of Formula I are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.

  本发明提供了式I的化合物，该化合物是5-脂氧合酶激活蛋白抑制剂：式(I)。式I的化合物可用作抗动脉粥样硬化、抗哮喘、抗过敏、抗炎和细胞保护剂。